Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Latest News about Phase 2 Trial
Recent news which mentions Phase 2 Trial
< Previous
1
2
3
4
5
6
7
8
9
Next >
Seagen's Tucatinib/Trastuzumab Combo Shows Encouraging Antitumor Activity In Pretreated Colorectal Cancer Patients
July 05, 2022
Tickers
SGEN
Tags
Market News
News
colorectal cancer
From
Benzinga
EXCLUSIVE: BioRestorative Selects Second Site For Its Lumbar Disc Disease Study
June 22, 2022
Tickers
BRTX
Tags
Penny Stocks
Phase 2 Trial
Health Care
From
Benzinga
Rocket Pharma's Gene Therapy Shows 100% Overall Survival In Immune Deficiency Disorder
May 19, 2022
Tickers
RCKT
Tags
Briefs
Biotech
Health Care
From
Benzinga
Applied Genetic's Vision Loss Gene Therapy Shows Encouraging Safety, Efficacy At Three Months
May 17, 2022
Tickers
AGTC
Tags
General
Benzinga
gene therapy
From
Benzinga
Urovant's OAB Gene Therapy Shows Improvement In Symptoms Compared To Placebo
May 13, 2022
Tickers
MYOV
Tags
Movers
Phase 2 Trial
Health Care
From
Benzinga
Rezolute's RZ358 Shows Around 75% Reduction In Hypoglycemia Events
May 02, 2022
Tickers
RZLT
Tags
Briefs
Biotech
Health Care
From
Benzinga
Kazia Therapeutics Concludes Mid-Stage Paxalisib Study In Brain Cancer
April 21, 2022
Tickers
KZIA
Tags
General
Benzinga
Market News
From
Benzinga
Windtree Reveals Encouraging Data From Istaroxime Study In Early Cardiogenic Shock
April 20, 2022
Tickers
WINT
Tags
Market News
News
Benzinga
From
Benzinga
Why Acadia Pharma Shares Are Falling Today
April 19, 2022
Tickers
ACAD
Tags
Biotech
ACAD
General
From
Benzinga
Sanofi's Rilzabrutinib Data In Autoimmune Blood Disorder Published In New England Journal of Medicine
April 14, 2022
Tickers
SNY
Tags
Briefs
Biotech
Health Care
From
Benzinga
AbbVie - Genmab Post Epcoritamab Data From Early-Stage Blood Cancer Study
April 14, 2022
Tickers
ABBV
GMAB
Tags
Briefs
Health Care
Biotech
From
Benzinga
EXCLUSIVE: Longeveron Adds Miami Veterans Affairs Site To Its Ongoing Mid-Stage Alzheimer's Trial
April 13, 2022
Tickers
LGVN
Tags
Health Care
Biotech
LGVN
From
Benzinga
AbbVie Releases New Data From Mid-Stage Navitoclax Combo Trial In Bone Marrow Cancer
April 12, 2022
Tickers
ABBV
Tags
Phase 2 Trial
Biotech
Health Care
From
Benzinga
Repare Therapeutics Shares Dip After Updated RP-3500 Data In Solid Tumors
April 12, 2022
Tickers
RPTX
Tags
Biotech
RPTX
General
From
Benzinga
IO Biotech Reveals Updated Data From IO102-IO103/Opdivo Combo Trial In Melanoma
April 11, 2022
Tickers
BMY
IOBT
Tags
Phase 2 Trial
Health Care
IOBT
From
Benzinga
IMV's MVP-S Doublet Combo Therapy Shows Encouraging Anti Tumor Activity
April 11, 2022
Tickers
IMV
MRK
Tags
MRK
Benzinga
General
From
Benzinga
VYNE Therapeutics Shares Gain After Positive Atopic Dermatitis Trial Of FMX114
April 07, 2022
Tickers
VYNE
Tags
General
News
Phase 1 Trial
From
Benzinga
Biophytis Shares Fall As It Stops Enrollment In Sarconeos COVID-19 Trial, Data Expected In Q3 2022
April 07, 2022
Tickers
BPTS
Tags
News
Market News
BPTS
From
Benzinga
Adverum Moves Forward With IND Amendment For ADVM-022 Phase 2 Trial In Wet AMD
April 07, 2022
Tickers
ADVM
Tags
ADVM
FDA
Biotech
From
Benzinga
Read Why Imara Shares Are Falling Today
April 05, 2022
Tickers
IMRA
Tags
Movers
Phase 2 Trial
Trading Ideas
From
Benzinga
BridgeBio Pharma Highlights Mid-Stage Study Data Of Acoramidis In Cardiomyopathy Trial
April 04, 2022
Tickers
BBIO
Tags
Phase 2 Trial
BBIO
Briefs
From
Benzinga
NRx Pharma Says I-SPY Study Of Inhaled Zyesami In Critical COVID-19 Stopped
March 31, 2022
Tickers
NRXP
Tags
Penny Stocks
COVID/19 Vaccine
Biotech
From
Benzinga
Portage Biotech Shares Encouraging Preliminary Safety Data From Lead iNKT Agonists Program In Cancer Patients
March 31, 2022
Tickers
BMY
MRK
PRTG
Tags
Health Care
Briefs
Phase 2 Trial
From
Benzinga
Why Are Immutep Shares Trading Higher?
March 30, 2022
Tickers
IMMP
Tags
Penny Stocks
Phase 2 Trial
IMMP
From
Benzinga
Biogen, Eisai Unveil New Data On Another Alzheimer's Candidate, Lecanemab
March 22, 2022
Tickers
BIIB
ESALF
ESALY
Tags
Biotech
BIIB
General
From
Benzinga
NLS Pharma Shares Fall After Mazindol ER Interim Data Shows 39% Improvement On Sleepiness Scale
March 16, 2022
Tickers
NLSP
Tags
General
News
NLSP
From
Benzinga
FDA Removes Clinical Hold On AIM ImmunoTech's Mid-Stage Ampligen Trial In Pancreatic Cancer
March 16, 2022
Tickers
AIM
Tags
Health Care
Trading Ideas
Briefs
From
Benzinga
Adagene Shares Pop After FDA Clears Phase 1b/2 Trial For ADG126/Keytruda Combo Therapy In Solid Tumors
March 16, 2022
Tickers
ADAG
MRK
Tags
ADAG
Biotech
FDA
From
Benzinga
AnaptysBio To Discontinue Imsidolimab Development In Moderate-to-Severe Acne
March 15, 2022
Tickers
ANAB
Tags
Movers
Phase 2 Trial
Health Care
From
Benzinga
GeoVax Labs Retains CATO SMS To Manage Its Mid-Stage COVID-19 Vaccine Trials
March 14, 2022
Tickers
BNTX
GOVX
MRNA
PFE
Tags
Market News
COVID/19 Coronavirus
News
From
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.